Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. The company reported a strong net cash position of Rs.2,756 crores as of December '23, indicating a comfortable liquidity status. They highlighted sufficient cash available for potential M&A and in-licensing opportunities. Management emphasized operational efficiency and maintaining EBITDA margins without indicating the need for external funding. No references were made to any plans for raising new debt or issuing equity in the near future during the Q3 FY24 call.

Any current/future capex/capital investment/strategic investment?

The CAPEX including capital work-in-progress was Rs.324 crores in the nine months of FY'24. The total CAPEX for FY'24 is expected to be less than Rs.500 crores. The company maintains a strong net cash position of Rs.2,756 crores, providing scope for potential M&A and in-licensing opportunities. Management emphasized continued focus on strategic acquisitions and in-licensing, particularly in chronic therapies and consumer healthcare. No further investment is planned in the Mahananda Resort, which is self-sustaining. The company is open to exploring monetization opportunities for non-core assets

Future growth expectations in sales/revenue/volumes?

Domestic business expected to grow double digits, driven by chronic therapies and base portfolio growth. Chronic segment contribution is rising; aim to exceed 40-50% long-term, supported by ramping up specialty chronic divisions. Modern trade and hospital sales (5-6% of total) growing rapidly and adding to overall volumes; expected to normalize next year. Export business projected to grow in high teens to double digits despite one-off opportunities tapering; new product launches and approvals anticipated. Consumer healthcare to recover and grow after recent quarter's corrective actions

IN US

Sale is live|00:00:00left today

Mankind Pharma LtdQ4 FY25Pharmaceuticals & Biotechnology

Mankind Pharma Ltd Q4 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,496P/E: 55.6Market Cap: ₹1.0L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Domestic business expected to grow double digits, driven by chronic therapies and base portfolio growth.
→Chronic segment contribution is rising; aim to exceed 40-50% long-term, supported by ramping up specialty chronic divisions.
→Modern trade and hospital sales (5-6% of total) growing rapidly and adding to overall volumes; expected to normalize next year.
→Export business projected to grow in high teens to double digits despite one-off opportunities tapering; new product launches and approvals anticipated.
→Consumer healthcare to recover and grow after recent quarter's corrective actions and channel consolidation.
→Dydrogesterone production at new Udaipur facility will scale up from next year, targeting both domestic and international demand.
→Overall volume growth expected to improve with focus on chronic therapies, modern trade, and new markets.
→EBITDA margins and growth expected to benefit from improving brand portfolio, chronic segment share, and MR productivity gains.

Margin guidance

Category 3

- **EBITDA Margins**: Targeted to maintain in the range of 24% to 26% for FY'24 and expected to improve with growth in chronic segment and specialty divisions. - **EBITDA Growth**: 39% YoY growth reported in Q3 FY'24, with expectations of further margin expansion driven by chronic portfolio, super specialty divisions, and brand creation. - **Profit After Tax (PAT)**: Robust growth of 55% YoY in Q3 FY'24; future growth expected due to operational efficiencies and strong domestic business. - **Earnings Per Share (EPS)**: Reported diluted EPS of Rs.11.3 for Q3 FY'24; cash EPS at Rs.14.1, indicating healthy earnings quality. - **Expense Growth**: Employee cost increase expected to be controlled, growing at a rate lower than overall company revenue growth. - **Chronic Segment**: Contribution increased from 28% (FY18/19) to 35% currently, with ambitions to reach 40-50% over the medium term, fueling earnings growth. - **Export Business**: Positive double-digit growth expected but not at prior year's exceptional levels. Overall, the company is confident about sustained earnings and margin expansion driven by chronic segment growth, increased MR productivity, and brand leverage.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
→The company reported a strong net cash position of Rs.2,756 crores as of December '23, indicating a comfortable liquidity status.
→They highlighted sufficient cash available for potential M&A and in-licensing opportunities.
→Management emphasized operational efficiency and maintaining EBITDA margins without indicating the need for external funding.
→No references were made to any plans for raising new debt or issuing equity in the near future during the Q3 FY24 call.

Order book

The transcript provided from the Mankind Pharma Q3 FY24 earnings call does not explicitly mention details about the current or expected order book or pending orders. Key financial and operational highlights discussed include: - Strong revenue growth of 25% in Q3 FY24. - Market share improvements and growth in chronic segment. - Robust growth in modern trade and export business (118% YoY). - Corrective measures taken in consumer healthcare leading to recovery. - Operational efficiencies leading to healthy cash flow and optimized working capital. - Expansion in manufacturing capacity and product launches. No specific data or commentary about order book size or pending orders are disclosed in the transcript sections provided.

Capex plans

Yes

→The CAPEX including capital work-in-progress was Rs.324 crores in the nine months of FY'24.
→The total CAPEX for FY'24 is expected to be less than Rs.500 crores.
→The company maintains a strong net cash position of Rs.2,756 crores, providing scope for potential M&A and in-licensing opportunities.
→Management emphasized continued focus on strategic acquisitions and in-licensing, particularly in chronic therapies and consumer healthcare.
→No further investment is planned in the Mahananda Resort, which is self-sustaining.
→The company is open to exploring monetization opportunities for non-core assets like Mahananda Resort when attractive.
→Expansion and capacity enhancement efforts continue, as highlighted by improvements in Sikkim plant operations.

How does Mankind Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Mankind Pharma Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Mankind Pharma Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio